Medicaid Drug Rebate Program - Manufacturers and Supporting Regulation at 42 CFR 447.534 (CMS-367)

ICR 201603-0938-023

OMB: 0938-0578

Federal Form Document

Forms and Documents
ICR Details
0938-0578 201603-0938-023
Historical Active 201603-0938-012
HHS/CMS
Medicaid Drug Rebate Program - Manufacturers and Supporting Regulation at 42 CFR 447.534 (CMS-367)
No material or nonsubstantive change to a currently approved collection   No
Regular
Approved without change 04/04/2016
Retrieve Notice of Action (NOA) 03/31/2016
  Inventory as of this Action Requested Previously Approved
03/31/2019 03/31/2019 03/31/2019
12,810 0 12,810
3,612,603 0 3,612,603
0 0 0

Section 1927 requires drug manufactures to enter into and have in effect a rebate agreement with the Federal Government for States to receive funding for drugs dispensed to Medicaid recipients. In order for payment to be made under Medicaid, the drug labeler must complete and sign a drug rebate agreement and fillin the information on the related documents. The Affordable Care Act (ACA) added two new data elements to potentially be reported by manufacturers, a Pediatric Exclusivity product indicator and a new optional "ACA base AMP" field. Additionally, per the ACA, the Federal upper limit (FUL) will be calculated as no less than 175 percent of the weighted average of the most recently reported monthly AMP. Section 1927 of the Act requires manufacturers to report the total number of units that are used to calculate monthly AMP for each covered outpatient drug no later than 30 days after the last day of the month. We plan to require manufacturers to report these units by the same unit type used to calculate the AMP and to use these units to calculate the weighted-AMP-based FULs prices.

Statute at Large: 19 Stat. 1927 Name of Statute: null
  
PL: Pub.L. 111 - 148 2503 Name of Law: Patient Protection and Affordable Care Act
PL: Pub.L. 111 - 226 202 Name of Law: Education Jobs and Medicaid Assistance Act

0938-AQ41 Final or interim final rulemaking 81 FR 5170 02/01/2016

  77 FR 5318 02/02/2012
81 FR 5170 02/01/2016
Yes

1
IC Title Form No. Form Name
Medicaid Drug Rebate Program - Manufacturers and Supporting Regulation at 42 CFR 447.534 (CMS-367) CMS-367a, CMS-367b, and CMS-367c Medicaid Drug Program Monthly and Quarterly Drug Reporting

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 12,810 12,810 0 0 0 0
Annual Time Burden (Hours) 3,612,603 3,612,603 0 0 0 0
Annual Cost Burden (Dollars) 0 0 0 0 0 0
No
No
The CMS-2345-FC (RIN 0938-AQ41) final rule adds burden which is set out in detail in section 15 of the Supporting Statement.

$750,000
No
No
Yes
No
No
Uncollected
Mitch Bryman 410 786-5258 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
03/31/2016


© 2024 OMB.report | Privacy Policy